1-9 of 9
Ariel Perez-Perez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rituximab Ibrutinib Lenalidomide (R2I) Combination for Primary or Secondary Large B-Cell CNS Lymphoma: Last Resort or Bridge to Cellular Therapy?

Ariel Perez Perez, Tiba Al Sagheer, George Nahas, Muni Rubens, Kristie Lopes, Yazmin Odia, Manmeet Ahluwalia, Zhijian Chen, Yuliya Linhares
Journal: Blood
Blood (2023) 142 (Supplement 1): 6275.
https://doi.org/10.1182/blood-2023-186488
Published: 2023
Journal Articles

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Grace Johnson, Kedar Patel, Brian Arciola, Ariel Perez Perez, Anthony Wood, Filip Ionescu, Jennifer M Logue, Omar Albanyan, Hassaan Yasin, Christina A Bachmeier, Kayla Reid, Meghan Menges, Salvatore Corallo, Bijal D. Shah, Julio C Chavez, Farhad Khimani, Taiga Nishihori, Rawan Faramand, Hien Liu, Aleksandr Lazaryan, Kai Rejeski, Marion Subklewe, Fabiana Perna, Marco Davila, Rahul Mhaskar, Frederick L. Locke, Michael D. Jain
Journal: Blood
Blood (2023) 142 (Supplement 1): 3512.
https://doi.org/10.1182/blood-2023-185097
Published: 2023
Journal Articles

Trial in Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-in

Yuliya Linhares, Ariel Perez Perez, Tiba Al Sagheer, George Nahas, Alex Mejia-Garcia, Muni Rubens, Talia Zahra, Lyle Feinstein, Lisa Reale, Marco Andres Ruiz, Peter L. Citron, Yazmin Odia, Guenther Koehne
Journal: Blood
Blood (2022) 140 (Supplement 1): 12061–12063.
https://doi.org/10.1182/blood-2022-167064
Published: 2022
Journal Articles

Polatuzumab- Rituximab with or without Bendamustine As Second-Line Therapy for Relapsed Refractory Large B-Cell Lymphomas: Single Center Experience

Ariel Perez Perez, Shreya Saxena, Tiba Al Sagheer, Muni Rubens, Talia Zahra, George Nahas, Alex V. Mejia Garcia, Lyle Feinstein, Lisa Reale, Marco Andres Ruiz, Peter L. Citron, Atulya Khosla, Manmeet Ahluwalia, Guenther Koehne, Yuliya P.L. Linhares
Journal: Blood
Blood (2022) 140 (Supplement 1): 6672–6673.
https://doi.org/10.1182/blood-2022-163461
Published: 2022
Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, Veit L Buecklein, Viktoria Blumenberg, Simon Voelkl, Olaf Penack, Omar Albanyan, Simon KG Forsberg, Agnese Petrera, Niklas Mueller, Kayla M. Reid, Rawan Faramand, Marco L. Davila, Michael von Bergwelt, Frederick L. Locke, Wolfgang Bethge, Lars Bullinger, Andreas Mackensen, Pere Barba, Michael D. Jain, Marion Subklewe
Journal: Blood
Blood (2022) 140 (Supplement 1): 4549–4551.
https://doi.org/10.1182/blood-2022-167632
Published: 2022
Journal Articles

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Veit L Buecklein, Ariel Perez-Perez, Kai Rejeski, Gloria Iacoboni, Vindi Jurinovic, Udo Holtick, Olaf Penack, Soraya Kharboutli, Viktoria Blumenberg, Josephine Ackermann, Lisa Frölich, Grace Johnson, Kedar Patel, Brian Arciola, Christian Schmidt, Omar Albanyan, Philipp Gödel, Eva Hoster, Lars Bullinger, Andreas Mackensen, Frederick L. Locke, Michael von Bergwelt, Pere Barba, Michael D. Jain, Marion Subklewe
Journal: Blood
Blood (2022) 140 (Supplement 1): 2411–2413.
https://doi.org/10.1182/blood-2022-165452
Published: 2022
Journal Articles

The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL

Kai Rejeski, Ariel Perez-Perez, Gloria Iacoboni, Olaf Penack, Veit L Buecklein, Liv Jentzsch, Dimitrios Mougiakakos, Grace Johnson, Brian Arciola, Viktoria Blumenberg, Cecilia Carpio, Eva Hoster, Lars Bullinger, Frederick L. Locke, Michael von Bergwelt, Andreas Mackensen, Wolfgang A Bethge, Pere Barba, Michael D. Jain, Marion Subklewe
Journal: Blood
Blood (2021) 138 (Supplement 1): 3852.
https://doi.org/10.1182/blood-2021-149579
Published: 2021
Journal Articles

Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy

Ariel Perez Perez, Grace Johnson, Kedar Patel, Brian Arciola, Anthony Wood, Christina A Bachmeier, Julio C. Chavez, Bijal D. Shah, Farhad Khimani, Taiga Nishihori, Aleksandr Lazaryan, Marco L. Davila, Rahul Mhaskar, Frederick L. Locke, Sameh Gaballa, Michael D. Jain
Journal: Blood
Blood (2021) 138 (Supplement 1): 3855.
https://doi.org/10.1182/blood-2021-150735
Published: 2021
Journal Articles

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Ariel Perez Perez, MD, Christina A Bachmeier, PharmD, Renee Smilee, Albert J Ribickas, Aleksandr Lazaryan, MDPhDMPH, Julio C. Chavez, MD, Claudio Anasetti, MD, Bijal Shah, MD, Farhad Khimani, MBBS, Taiga Nishihori, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Hien D. Liu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-143336
Published: 2020